Clinical trial to investigate liraglutide's effects on insulin detemir pharmacokinetics

Managing Type 2 Diabetes often involves combination therapies, including GLP-1 receptor agonists like liraglutide and basal insulins such as insulin detemir. While both are effective for glycemic control, understanding potential pharmacokinetic interactions is crucial. Such interactions could impact drug efficacy, alter dosing requirements, or increase the risk of adverse events like hypoglycemia. This trial addresses a critical gap by specifically examining how chronic liraglutide administration might modify the absorption, distribution, metabolism, and excretion (pharmacokinetics) of insulin detemir.

This clinical trial, conducted in the United States, was designed to investigate the potential impact of chronic liraglutide administration on the mode of action (pharmacokinetics) of insulin detemir. The study's primary objective is to determine if co-administration of these two agents leads to changes in how insulin detemir is processed by the body. Specific details regarding patient population, sample size, exact dosing regimens, duration of treatment, or primary endpoints were not provided in this abstract.